非肌层浸润性膀胱癌TURBT术后黏膜下注射吡柔比星联合丝裂霉素灌注的疗效观察  

Clinical study on submucosal injection of pirarubicin combined with instillation of mitomycin after TURBT in patients with non-muscle invasive bladder cancer

作　　者：王磊[1] 刘致中[1] 赵海涛[1] 岳长久[1] 李建新[1] 韩利忠[1] 

机构地区：[1]内蒙古医科大学第三附属医院包钢医院泌尿外科,内蒙古包头014010

出　　处：《临床泌尿外科杂志》2014年第2期125-127,共3页Journal of Clinical Urology

摘　　要：目的：评价经尿道膀胱肿瘤电切术（TURBT）后即刻黏膜下注射吡柔比星（THP）联合丝裂霉素（MMC）灌注治疗非肌层浸润性膀胱癌患者的疗效和安全性。方法：63例膀胱尿路上皮细胞癌患者TURBT术中行THP注射后1年内规律MMC膀胱灌注，每周1次连续8周，每2周1次连续8次，每个月1次连续6次，术后每3个月复查膀胱镜。结果：术后随访2个月～3年，复发率15．9％；灌注期间6例出现不同程度副反应，1例术后8个月发生全身性骨转移，1例术后3年死亡。结论：THP膀胱内注射联合MMC定期灌注用于膀胱癌术后预防肿瘤复发效果明显、安全、可靠。Objective： To evaluate the efficacy and safety of immediate submucosal injection of pirarubicin （THP） combined with intravesical instillation of mitomycin （MMC） after TURBT in patients with non-muscle in- vasive bladder cancer. Method： The data of 63 patients with bladder urothelial cell carcinoma underwent TURBT were retrospectively analyzed. After immediate injected of THP after TURBT, the patients were received postop- erative intravesieal instillation of MMC once a week for eight weeks, later once every two weeks for four months, and at last once a month for six months. Cystoseopy was taken once every three months postoperatively. Result： The recurrence rate was 15.9% after follow-up period of 2 months-3 years. Six cases of side effects, one case of systemic hone metastasis and one case of death took place during intravesical instillation of MMC within three years postoperatively. Conclusion.. Postoperative prophylactic submucosal injection of THP combined with regular intravesical instillation of MMC is effective and safe for prevention of recurence of bladder carcinoma after the op- eration.

关 键 词：膀胱癌 丝裂霉素 吡柔比星 术后灌注 

分 类 号：R737.14[医药卫生—肿瘤]